Lack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancer

BACKGROUND: ErbB2 Receptor Tyrosine Kinase 2 (ErbB2, HER2/Neu) is amplified in breast cancer and associated with poor prognosis. Growing evidence suggests interplay between ErbB2 and insulin-like growth factor (IGF) signaling. For example, ErbB2 inhibitors can block IGF-induced signaling while, conv...

Descripción completa

Detalles Bibliográficos
Autores principales: Farabaugh, Susan M., Chan, Bonita T., Cui, Xiaojiang, Dearth, Robert K., Lee, Adrian V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073819/
https://www.ncbi.nlm.nih.gov/pubmed/27765041
http://dx.doi.org/10.1186/s12964-016-0148-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073819/
https://www.ncbi.nlm.nih.gov/pubmed/27765041
http://dx.doi.org/10.1186/s12964-016-0148-8

Ejemplares similares